|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
FLAG-tag, or FLAG octapeptide, is a polypeptide protein tag that can be added to a protein using recombinant DNA technology. It can be used for affinity chromatography, then used to separate recombinant, overexpressed protein from wild-type protein expressed by the host organism. It can also be used in the isolation of protein complexes with multiple subunits.
A FLAG-tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a FLAG-tag to this protein allows one to follow the protein with an antibody against the FLAG sequence. Examples are cellular localization studies by immunofluorescence or detection by SDS PAGE protein electrophoresis.
The peptide sequence of the FLAG-tag from the N-terminus to the C-terminus is: DYKDDDDK (1012 Da). It can be used in conjunction with other affinity tags, for example a polyhistidine tag (His-tag), HA-tag or myc-tag. It can be fused to the C-terminus or the N-terminus of a protein. Some commercially available antibodies (e.g., M1/4E11) recognize the epitope only when it is present at the N-terminus. However, other available antibodies (e.g., M2) are position-insensitive.
|Mouse GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, C-GFPSpark tag||MG51048-ACG|
|Mouse GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, C-OFPSpark tag||MG51048-ACR|
|Mouse GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, C-Flag tag||MG51048-CF|
|Mouse GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, C-His tag||MG51048-CH|
|Mouse GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, C-Myc tag||MG51048-CM|
|Mouse GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, C-HA tag||MG51048-CY|
|Mouse GM-CSF/CSF2 Gene ORF cDNA clone in cloning vector||MG51048-G|
|Mouse GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, N-Flag tag||MG51048-NF|
|Mouse GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, N-His tag||MG51048-NH|
|Mouse GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, N-Myc tag||MG51048-NM|
|Mouse GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, N-HA tag||MG51048-NY|
|Mouse GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid||MG51048-UT|
|Learn more about expression Vectors|
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.